BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2023 on Thursday, April 27, 2023.

Abata Therapeutics today announced the appointment of David Kaufman, M.D., Ph.D., partner at Third Rock Ventures, to its board of directors.

IMV Inc. today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company’s 2022 fourth quarter and fiscal year-end financial and operational results.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO ®.

Black Diamond Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended December 31, 2022, and highlighted recent progress.

Akebia Therapeutics®, Inc. today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided business highlights.

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022.

Palvella Therapeutics, Inc. today announced positive topline results from the Company’s Phase 2 study of QTORIN™ rapamycin in Microcystic Lymphatic Malformations (Microcystic LM). Microcystic LM is a rare, chronically debilitating genetic disease caused by dysregulation of the PI3K/mTOR pathway.